ArticleScientific reports2025
Efficacy of combined TAE, HAIC, targeted, and immunotherapy in unresectable HCC: a multicenter propensity score matching study.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A habitat radiomics model based on contrast-enhanced MRI for predicting early treatment response to hepatic arterial infusion chemotherapy in patients with unresectable hepatocellular carcinoma.Cellular oncology (Dordrecht, Netherlands) · 2026Article
- Article
- Clinical Efficacy Exploration of Temperature-Sensitive Embolic Agent TACE Combined with HAIC and Targeted/Immunotherapy for Unresectable Primary Liver Cancer.Journal of hepatocellular carcinoma · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Hepatocellular carcinoma is a leading cause of cancer-related death, with unresectable HCC (uHCC) presenting considerable clinical challenges; treatment options are limited, warranting the combination of locoregional therapies. We compared the efficacy of transcatheter arterial embolization-hepatic artery infusion chemotherapy (TAE-HAIC) plus targeted therapy and immunotherapy to other therapeutic combinations for treating uHCC. We conducted a multicenter, retrospective cohort study, utilizing propensity score matching to compare treatment outcomes between patients receiving TAE-HAIC with targeted therapy and immunotherapy and those receiving other combination therapies. Data were collected from multiple centers, and survival outcomes, tumor control, and overall efficacy were evaluated between matched groups. TAE-HAIC plus targeted therapy and immunotherapy significantly improved overall survival and progression-free survival compared to other therapeutic combinations. The combination therapy demonstrated superior tumor control rates and a reduced risk of disease progression. Statistically significant improvements in survival metrics and clinical outcomes were observed in the TAE-HAIC group, underscoring the efficacy of this approach. This study supports the use of TAE-HAIC combined with targeted therapy and immunotherapy for patients with uHCC. These findings offer valuable insights into optimizing treatment strategies and highlight the potential for this combination to improve patient outcomes and survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.